Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14805424 | 1.00 | BTK (0.55) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL471721 | 1.00 | BTK (0.55) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL2262867 | 0.90 | BTK (0.53) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL470721 | 0.90 | BTK (0.53) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL2262870 | 0.90 | BTK (0.53) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL19364082 | 0.90 | BTK (0.53) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL471058 | 0.90 | BTK (0.53) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL28193535 | 0.83 | PPM1B (0.41) | BTKNFKB1JAK1JAK2 | |
| SCHEMBL3702152 | 0.80 | BTK (0.61) | BTKCTSKGAAKDM1AMAOB | |
| SCHEMBL3702157 | 0.80 | BTK (0.61) | BTKCTSKGAAKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218713-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20210113571-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2021-04-22 | — | — | US | disclosed |
| US-20200281933-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |
| US-20200030335-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2020-01-30 | — | — | US | disclosed |
| US-20190175603-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
| US-20180303842-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2018-10-25 | — | — | US | disclosed |
| US-20170266194-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| EP-2380874-B1 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2016-12-28 | — | — | EP | disclosed |
| EP-2321272-B1 | ORGANIC COMPOUNDS | NABRIVA THERAPEUTICS AG (AT) | 2016-04-20 | — | — | EP | disclosed |
| EP-2137143-B1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2011-09-07 | — | — | EP | disclosed |
| US-20110184022-A1 | Organic Compounds | NABRIVA THERAPEUTICS AG (AT) | 2011-07-28 | — | — | US | disclosed |
| EP-2321272-A1 | ORGANIC COMPOUNDS | Nabriva Therapeutics AG (AT) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010025482-A1 | ORGANIC COMPOUNDS | NABRIVA THERAPEUTICS AG (AT) | 2010-03-11 | — | — | WO | disclosed |
| EP-2159220-A1 | Organic compounds | Nabriva Therapeutics AG (AT) | 2010-03-03 | — | — | EP | disclosed |
| US-20100035987-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2010-02-11 | — | — | US | disclosed |
| EP-2137143-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics AG (AT) | 2009-12-30 | — | — | EP | disclosed |
| US-20090118366-A1 | ORGANIC COMPOUNDS | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2009-05-07 | — | — | US | disclosed |
| WO-2008113089-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2008-09-25 | — | — | WO | disclosed |
| EP-1972618-A1 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | Nabriva Therapeutics AG (AT) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281933-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | BTK 3454/4885CTSK 2333/4885GAA 249/4885 |
| US-20090118366-A1 | ORGANIC COMPOUNDS | C5, C9, C1S | BTK 3278/4885CTSK 1611/4885GAA 3993/4885 |
| US-20110184022-A1 | Organic Compounds | AHR, MAFK, MAFG | BTK 2525/4885CTSK 984/4885GAA 502/4885 |
| US-20220218713-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | BTK 3406/4885CTSK 2285/4885GAA 254/4885 |
| US-20190175603-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | BTK 3454/4885CTSK 2333/4885GAA 249/4885 |
| US-20170266194-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HRH4, HRH2, CHRM1 | BTK 4170/4885CTSK 4719/4885GAA 4787/4885 |
| US-20100035987-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, FABP6, ALPI | BTK 3006/4885CTSK 2731/4885GAA 129/4885 |
| US-20200030335-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HRH4, HRH2, CHRM1 | BTK 4170/4885CTSK 4719/4885GAA 4787/4885 |
| US-20210113571-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | BTK 3406/4885CTSK 2285/4885GAA 254/4885 |
| US-20180303842-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | BTK 3454/4885CTSK 2333/4885GAA 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.